



CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS

Award ID:
DP160014

Project Title:
Salarius Pharmaceuticals - Developing epigenetic drugs that treat Rare Pediatric Cancers

Award Mechanism:
New Company Product Development Award

Principal Investigator:
Arthur, David

Entity:
Salarius Pharmaceuticals LLC

Lay Summary:

Salarius specializes in developing novel drugs for rare pediatric cancers and other cancers by focusing on treatments that interrupt the final steps of the signaling cascade.

Our first drug, SP-2577, targets the Lysine Specific Histone Demethylase 1 pathway (LSD1), a cellular control protein that's overactive in a range of cancers. Here Salarius has developed a first in class highly specific LSD1 inhibitor that we will test in Ewing's Sarcoma and other undifferentiated sarcomas, in addition to late stage prostate cancer. We plan to file an IND in early 2016 and initiate phase 1 clinical studies in Ewing's and prostate cancer in June 2016.

Ewing's is a rare devastating pediatric, adolescent and young adult bone cancer with no approved treatment. Roughly 50% of Ewing's patients fail to respond to chemotherapy, radiation and surgical treatment and face 70%-80% mortality. If successful, a treatment for Ewing's Sarcoma represents hope for thousands of patients and their families where current treatments are often woefully inadequate. Successful phase 1/2 studies could support an accelerated regulatory process with a Ewing's orphan drug indication approved by Q3'19.

Salarius plans to relocate to Texas and set up a collaborative research effort to discover new drugs in its quest to become an integrated pharmaceutical company. Our business model is based on tight integration with academia and creating win-win environments between Salarius and academic cancer centers.